REPRISE China - Clinical Evaluation in China

首次发布于 2017 年 3 月 21 日

SYNERGY China: Assess SYNERGY Stent in China

计划入组 103 人 · 首次发布于 2015 年 7 月 16 日

no Antibiotics for Elective Cesarean With Low Risk of Infection

计划入组 212 人 · 首次发布于 2014 年 4 月 29 日

Domvanalimab biosimilar(PPC China)

11a(China Pharmaceutical University)

B9(China Pharmaceutical University)

HUTCHMED (China) Ltd.

China

Hutchmed Limited

China

HUTCHMED (Hong Kong) Limited

China

Analysts Maintain Bullish Stance on HUTCHMED (China) with Buy Ratings and Price Targets Above HK$32

Fruzaqla (Fruquintinib) Launched in Japan by Takeda for Metastatic Colorectal Cancer

HUTCHMED Announces Savolitinib sNDA Accepted in China for NSCLC Treatment